Skip to main content

Tyra Biosciences, Inc.

corporate_fare Company Profile

Tyra Biosciences, Inc.

TYRA·NASDAQ·Life Sciences·CIK 0001863127

TYRA Biosciences is a clinical-stage biotechnology company developing precision medicines for targeted oncology and genetically defined conditions, utilizing Fibroblast Growth Factor Receptor (FGFR) biology. The company employs its in-house SNÅP precision medicine platform for drug design, aiming to identify product candidates with high potency, selectivity, and tolerability. This approach has resulted in a wholly-owned pipeline of oral small molecule product candidates targeting previously difficult-to-drug areas. TYRA Biosciences' FGFR3 Programs include oral dabogratinib (formerly TYRA-300) for Urothelial Cancers and Skeletal Dysplasia. Alterations in the FGFR3 protein receptor are a validated driver in urothelial cancers, where uncontrolled activation stimulates cellular proliferation, and in skeletal dysplasia conditions, where increased FGFR3 activity in growth plate chondrocytes limits long bone growth. Oral dabogratinib was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to reduce off-target side effects. To date, oral dabogratinib has been administered to over 100 participants across multiple clinical studies. Initial clinical proof-of-concept results were demonstrated in the SURF301 study, a Phase 1 proof-of-concept study in metastatic urothelial carcinoma (mUC). In this study, oral dabogratinib showed encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2- and FGFR1-associated toxicities. Data from this study informed dose selection for future Phase 2 trials.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for TYRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for TYRA spans 8-K, SCHEDULE 13D/A, 424B5, FWP.

Recent high-impact activity:

  • Tyra Biosciences Posts 74c Quarterly Loss, Cash of $700.5M
  • Tyra Posts Q3 Loss of $51.1M, $700.5M Cash Funds Dabogratinib Through 2030
  • RA Capital Discloses $200M Pre-Funded Warrant Purchase in Tyra's $400M Offering
  • Tyra Biosciences Prices $400M Underwritten Offering at $22.03/Share
  • Tyra Biosciences Finalizes $400M Underwritten Offering at $22.03/Share

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$119.95M
Diluted EPS
-$2.01
Op. Cash Flow
-$95.14M
Free Cash Flow
-$95.28M
Operating Income
-$132.76M
Cash & Equivalents
$77.39M
Debt / Equity
0.00×
Shares Outstanding
53.71M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-085490

Short Interest & Short Volume

15.28 days to cover

FINRA reported short interest of 9,901,757 shares in TYRA as of the October 30, 2026 settlement, a 4.3% increase from the prior period — about 15.3 days to cover at its recent average daily volume. On November 20, 2026, 73.8% of TYRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,901,757 shares as of October 30, 2026
Change vs prior period▲ 4.3%
Days to cover15.28 at avg daily volume of 647,829
Daily short volume (FINRA facilities)73.8% of 117,553 shares on November 20, 2026
5-day average short volume74.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for TYRA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-14.

2 recent capital raisesATM program1 shelf registration

$400M Underwritten Offering Priced · Net Proceeds of $373.9M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$20.29 +0.84% today
52-week range · as of 2026-11-10 $13.83 – $40.65
Market cap
$1.39B
Volume
467.6K (0.8× avg)
3-mo avg 589.6K
Live data · 2026-11-22 06:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TYRA - Latest Insights

TYRA
Nov 10, 2026, 8:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $22.25
Real-time Price: $20.29 info
Change: -$1.96 (-9%) info
Market Cap: $1.39B info
TYRA
Nov 10, 2026, 8:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.25
Real-time Price: $20.29 info
Change: -$1.96 (-9%) info
Market Cap: $1.39B info
TYRA
Sep 17, 2026, 4:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $24.43
Real-time Price: $20.29 info
Change: -$4.14 (-17%) info
Market Cap: $1.39B info
TYRA
Sep 14, 2026, 7:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $20.29 info
Change: -$4.91 (-19%) info
Market Cap: $1.39B info
TYRA
Sep 14, 2026, 7:09 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $20.29 info
Change: -$4.91 (-19%) info
Market Cap: $1.39B info
TYRA
Sep 14, 2026, 6:45 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $21.70
Real-time Price: $20.29 info
Change: -$1.41 (-6%) info
Market Cap: $1.39B info
TYRA
Sep 14, 2026, 6:33 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $20.29 info
Change: -$1.41 (-6%) info
Market Cap: $1.39B info
TYRA
Sep 09, 2026, 7:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $20.00
Real-time Price: $20.29 info
Change: +$0.290 (+1%) info
Market Cap: $1.39B info
TYRA
Sep 09, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.22
Real-time Price: $20.29 info
Change: -$1.93 (-9%) info
Market Cap: $1.39B info
TYRA
Aug 04, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $31.18
Real-time Price: $20.29 info
Change: -$10.89 (-35%) info
Market Cap: $1.39B info
TYRA
Aug 04, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.40
Real-time Price: $20.29 info
Change: -$12.11 (-37%) info
Market Cap: $1.39B info
TYRA
May 13, 2026, 8:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $34.52
Real-time Price: $20.29 info
Change: -$14.23 (-41%) info
Market Cap: $1.39B info
TYRA
May 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.37
Real-time Price: $20.29 info
Change: -$14.08 (-41%) info
Market Cap: $1.39B info
TYRA
Apr 17, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $34.84
Real-time Price: $20.29 info
Change: -$14.55 (-42%) info
Market Cap: $1.39B info
TYRA
Mar 04, 2026, 5:18 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.99
Real-time Price: $20.29 info
Change: -$14.70 (-42%) info
Market Cap: $1.39B info
TYRA
Mar 02, 2026, 4:27 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $32.52
Real-time Price: $20.29 info
Change: -$12.23 (-38%) info
Market Cap: $1.39B info
TYRA
Mar 02, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.52
Real-time Price: $20.29 info
Change: -$12.23 (-38%) info
Market Cap: $1.39B info
TYRA
Mar 02, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $32.52
Real-time Price: $20.29 info
Change: -$12.23 (-38%) info
Market Cap: $1.39B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets